Abstract:Valganciclovir, the ganciclovir prodrug, is an antiviral agent administered orally to prevent or treat cytomegalovirus infection in solid-organ transplant recipients. The valganciclovir dosing regimen in children is still controversial, as the number of patients reaching the area under the concentration-time curve at steady state (AUCss) target (40 to 60 mg·h/liter) remains highly variable. ABSTRACT Valganciclovir, the ganciclovir prodrug, is an antiviral agent administered orally to prevent or treat cytomegalovirus infection in solid-organ transplant recipients. The valganciclovir dosing regimen in children is still controversial, as the number of patients reaching the area under the concentration-time curve at steady state (AUCss) target (40 to 60 mg·h/liter) remains highly variable. The aim of this study was to determine the population pharmacokinetics of valganciclovir in pediatric renal transplant recipients and propose an appropriate dosing regimen. Children with renal transplant who received valganciclovir to prevent or treat cytomegalovirus infection at the Robert Debré University Hospital were included. Plasma ganciclovir concentrations were determined by high-performance liquid chromatography and UV detection. Population pharmacokinetic analysis was performed with NONMEM software. A total of 104 patients aged 2 to 20 years treated with valganciclovir, administered at a mean dose of 17.3 ± 6.1 mg/kg of body weight to prevent and/or treat cytomegalovirus infection after renal transplantation, were included. A total of 1,212 samples were available. A two-compartment model with first-order elimination best fitted the data: ganciclovir clearance increased with body surface area, was 15% higher in boys than in girls, and decreased with increasing creatinine concentration. The central volume of distribution increased with body surface area and was 14% higher in boys than in girls. According to the personalized dosing regimen, 65.7% and 65.4% of the children were predicted to achieve the AUCss target for cytomegalovirus prophylaxis and treatment, respectively. A new pharmacokinetic model that allows the proposal of an individualized dose adapted to the characteristics of pediatric patients with renal transplant was built.

Optimization of Ganciclovir and Valganciclovir Starting Dose in Children by Machine Learning

Application of machine-learning models to predict the ganciclovir and valganciclovir exposure in children using a limited sampling strategy

Individualization of Valganciclovir Prophylaxis for Cytomegalovirus Infection in Pediatric Kidney Transplant Patients

Population Pharmacokinetics of Ganciclovir Following Administration of Valganciclovir in Paediatric Renal Transplant Patients

Optimizing Ganciclovir and Valganciclovir Dosing Regimens in Pediatric Patients with Cytomegalovirus Infection: a Spotlight on Therapeutic Drug Monitoring

Population Pharmacokinetics and Dose Optimization of Ganciclovir in Critically Ill Children

Population Pharmacokinetics of Ganciclovir after Valganciclovir Treatment in Children with Renal Transplant

Establishment and Evaluation of a Parametric Population Pharmacokinetic Model Repository for Ganciclovir and Valganciclovir.

Pilot Study of Model-Based Dosage Individualization of Ganciclovir in Neonates and Young Infants with Congenital Cytomegalovirus Infection

Use of Machine Learning for Dosage Individualization of Vancomycin in Neonates

Serum ganciclovir drug exposure in children receiving standard ganciclovir dosing

Optimizing vancomycin dosing in pediatrics: a machine learning approach to predict trough concentrations in children under four years of age

Valganciclovir Pharmacokinetics in Patients Receiving Oral Prophylaxis Following Kidney Transplantation and Model-Based Predictions of Optimal Dosing Regimens

Application of machine learning combined with population pharmacokinetics to improve individual prediction of vancomycin clearance in simulated adult patients

Impact of pharmacogenetics on variability in exposure to oral vinorelbine among pediatric patients: a model-based population pharmacokinetic analysis

Vancomycin Population Pharmacokinetic Modeling in Children Using Bayesian Estimation and a Non Parametric Approach

Optimization of Vancomycin Initial Dosing Regimen in Neonates Using an Externally Evaluated Population Pharmacokinetic Model

Individualized medication model of vancomycin in patients with renal insufficiency using machine learning techniques

A New Algorithm Optimized for Initial Dose Settings of Vancomycin Using Machine Learning

Pharmacokinetic and Pharmacodynamic Assessment of Valganciclovir in Infants With Congenital Cytomegalovirus Infection

Population pharmacokinetic analysis for dose regimen optimization of vancomycin in Southern Chinese children